BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Inverness Medical Innovations, Inc. (IMA) Announces Agreement To Supply Pfizer Inc. (PFE) With A Digital Version Of Its e.p.t(R) Brand Pregnancy Test


10/19/2005 5:09:32 PM

WALTHAM, Mass., Dec. 17 /PRNewswire-FirstCall/ -- Inverness Medical Innovations, Inc., through its subsidiary, Unipath, Ltd., recently entered into an agreement to supply Warner-Lambert Company LLC, a wholly-owned subsidiary of Pfizer Inc. ("Pfizer") a digital version of Pfizer's premium- branded e.p.t(R) pregnancy test. Under the agreement, which is non-exclusive, Inverness generally is obligated to fulfill Pfizer's product orders through November 1, 2008 (subject to certain early termination events), at fixed prices subject to certain adjustments. Inverness has commenced product shipments under this agreement. Under another agreement previously entered into with Pfizer, Inverness has agreed to supply Pfizer with its requirements for the visual/non-digital e.p.t(R) pregnancy test beginning in June 2004 and continuing for five years. That agreement includes minimum purchase obligations. Pfizer's purchases of digital pregnancy tests under the new agreement will be credited against these minimum quantities.

Inverness will continue to market its premium-branded Clearblue(R) Easy digital pregnancy test.

For more information about Inverness Medical Innovations, please visit our website at http://www.invmed.com/.

Inverness Medical Innovations is a leading provider of women's health and other consumer and point-of-care health products and a developer of advanced technologies for both the consumer and professional diagnostic marketplaces. Inverness is presently exploring new opportunities for its proprietary electrochemical and other technologies in a variety of consumer oriented applications including immuno-diagnostics with a focus on women's health and cardiology. Inverness is headquartered in Waltham, Massachusetts.

Clearblue is a registered trademark of Inverness Medical Switzerland GmbH.

e.p.t is a registered trademark of Warner-Lambert Company LLC, a subsidiary of Pfizer Inc.

Contact: Doug Guarino, Director of Corporate Relations 781 647-3900 Chris Lindop, Chief Financial Officer 781 314-4097

Inverness Medical Innovations, Inc.

CONTACT: Doug Guarino, Director of Corporate Relations, +1-781 647-3900,or Chris Lindop, Chief Financial Officer, +1-781 314-4097, both of InvernessMedical Innovations



Read at BioSpace.com

   
Pregnancy

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES